drugset / Trial / NCT01161394
Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study
Phase 4
Completed
24 enrolled
University at Buffalo
Takeda Pharmaceuticals North America, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Pioglitazone decreases oxidative load, inflammatory end points and improves vascular reactivity in obese patients in a dose dependent manner and that this effect is independent of its glucose lowering effects.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2003-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pioglitazone | Small molecule | 15 mg | — |
| Subject | Pioglitazone | Small molecule | 30 mg | — |
Indications
No indication recorded.